Association of IFITM3 rs12252 polymorphisms, BMI, diabetes, and hypercholesterolemia with mild flu in an Iranian

Parvaneh Mehrbod1, Sana Eybpoosh2, Fatemeh Fotouhi1

  • 1Influenza and Other Respiratory Viruses Department, Pasteur Institute of Iran, Tehran, Iran.

Virology Journal
|November 11, 2017
PubMed
Abstract

Insights

The rs12252 C allele is linked to a higher risk of mild flu in Iranians. This genetic marker may aid in early susceptibility screening for mild flu.

Area of Science:

  • Genetics
  • Infectious Diseases
  • Epidemiology

Background:

  • Interferon-induced transmembrane protein 3 (IFITM3) gene polymorphisms are implicated in infection susceptibility.
  • Diabetes and hypercholesterolemia are known risk factors for infections.
  • Investigating genetic and clinical factors for mild flu in the Iranian population is crucial.

Purpose of the Study:

  • To examine the association between the rs12252 C polymorphism, body mass index (BMI), diabetes, and hypercholesterolemia with mild flu susceptibility.
  • To evaluate the rs12252 T/C polymorphism in the Iranian population.
  • To identify potential genetic markers for mild flu risk.

Main Methods:

  • A case-control study involving 79 mild flu cases and 125 controls from Iran.
  • Real-time PCR and sequencing were used to determine rs12252 T/C genotypes.
  • Data on clinical and demographic variables were collected and analyzed using statistical software.

Main Results:

  • The allele frequency for rs12252-C was 9.49% in cases and 2.40% in controls.
  • Carriage of the rs12252 C allele (CT + CC genotypes) significantly increased mild flu risk (5.92-fold increase, P=0.007).
  • A significant association was found between rs12252 C allele heterozygosity and mild flu (OR=7.62, P=0.008), but not homozygosity.

Conclusions:

  • This study is the first to link rs12252 polymorphism to mild flu in Iranians.
  • Mild flu is significantly associated with rs12252 C allele heterozygosity and carriage.
  • The rs12252 polymorphism may serve as a genetic marker for mild flu susceptibility screening.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
24
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
18
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
460